<!DOCTYPE html>
<html>
<head>
    <title>Critical Review: Diabetes Prevention Program Trial</title>
    <link rel="stylesheet" href="style.css">
</head>
<body>

<h1>What I Learned from the Diabetes Prevention Program Trial: A Critical Review</h1>
<p><strong>By Vandna | Pharmacy Portfolio</strong></p>

<p>
During my course on critically interpreting randomized clinical trials (RCTs), 
I analyzed the landmark Diabetes Prevention Program published in 2002. 
This study compared intensive lifestyle modification with metformin therapy 
for preventing type 2 diabetes in high-risk individuals.
</p>

<hr>

<h2>Background: Why This Study Matters</h2>

<p>
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder associated 
with serious complications such as cardiovascular disease, neuropathy, 
nephropathy, and retinopathy. Individuals with impaired glucose tolerance (IGT) 
are at particularly high risk.
</p>

<p><strong>Clinical Question:</strong><br>
Can intensive lifestyle intervention or metformin therapy prevent or delay 
the onset of type 2 diabetes in high-risk individuals?
</p>

<hr>

<h2>Study Design: Understanding the Methodology</h2>

<p>
The Diabetes Prevention Program was a multicenter randomized controlled trial 
conducted across 27 centers in the United States.
</p>

<h3>Participants</h3>
<ul>
    <li>3,234 adults</li>
    <li>BMI ≥ 24 kg/m² (≥ 22 kg/m² for Asians)</li>
    <li>Impaired fasting glucose and impaired glucose tolerance</li>
    <li>Mean age: 51 years</li>
</ul>

<h3>Randomization Groups</h3>
<ol>
    <li><strong>Intensive Lifestyle Intervention</strong>
        <ul>
            <li>≥7% weight loss target</li>
            <li>≥150 minutes of moderate physical activity per week</li>
            <li>Structured behavioral counseling</li>
        </ul>
    </li>

    <li><strong>Metformin Group</strong>
        <ul>
            <li>850 mg twice daily</li>
        </ul>
    </li>

    <li><strong>Placebo Group</strong></li>
</ol>

<p>
The metformin and placebo arms were double-blinded. The lifestyle arm 
could not be blinded due to the nature of the intervention.
Participants were followed for an average of 2.8 years.
</p>

<hr>

<h2>Statistical Results: What the Numbers Showed</h2>

<h3>Incidence Rates</h3>
<ul>
    <li>Placebo group: 11.0 cases per 100 person-years</li>
    <li>Metformin group: 7.8 cases per 100 person-years</li>
    <li>Lifestyle group: 4.8 cases per 100 person-years</li>
</ul>

<h3>Relative Risk Reduction</h3>
<ul>
    <li>Lifestyle intervention reduced diabetes incidence by 58%</li>
    <li>Metformin reduced incidence by 31%</li>
</ul>

<h3>Statistical Significance</h3>
<ul>
    <li>Lifestyle vs placebo: p &lt; 0.001</li>
    <li>Metformin vs placebo: p &lt; 0.001</li>
</ul>

<p>
The confidence intervals did not cross unity, indicating a true treatment effect.
The study used intention-to-treat analysis, strengthening reliability.
The trial was stopped early due to clear benefit of lifestyle intervention.
</p>

<hr>

<h2>Strengths of the Study</h2>
<ul>
    <li>Large sample size (3,234 participants)</li>
    <li>Randomized controlled design</li>
    <li>Multicenter trial</li>
    <li>Ethnically diverse population</li>
    <li>Diagnosis confirmed with repeat testing</li>
    <li>Intention-to-treat analysis</li>
    <li>Strong statistical significance</li>
</ul>

<hr>

<h2>Limitations of the Study</h2>
<ul>
    <li>Lifestyle intervention may not be easily replicable in real-world settings</li>
    <li>Adherence may vary outside controlled conditions</li>
    <li>Lifestyle arm was not blinded (potential performance bias)</li>
    <li>High cost and resource intensity</li>
</ul>

<hr>

<h2>Clinical Implications</h2>

<ul>
    <li>Lifestyle modification should be first-line preventive strategy</li>
    <li>Metformin is useful in high-risk individuals unable to maintain lifestyle changes</li>
    <li>Prevention strategies significantly reduce long-term disease burden</li>
</ul>

<p>
This trial shifted the focus from treatment to prevention and demonstrated 
that behavioral interventions can produce measurable, statistically 
significant clinical impact.
</p>

<hr>

<h2>Reference</h2>

<p>
Knowler WC, Barrett-Connor E, Fowler SE, et al. (2002). 
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 
<em>New England Journal of Medicine</em>, 346(6), 393–403.
</p>

<p>
DOI: <a href="https://doi.org/10.1056/NEJMoa012512" target="_blank">
https://doi.org/10.1056/NEJMoa012512
</a>
</p>

<p><a href="index.html">← Back to Home</a></p>

</body>
</html>





